Genetesis

Genetesis is a healthcare technology company founded in 2013, specializing in non-invasive diagnostic tools for cardiac conditions. The company’s flagship product, CardioFlux, is a magnetocardiography (MCG) device that measures the natural magnetic fields produced by the heart. CardioFlux provides rapid, dynamic results in as little as 5 minutes and has been designed to be a radiation-free, stress-free, and injection-free alternative for diagnosing myocardial ischemia and infarction. The device has received FDA 510(k) clearance in 2019 and was granted Breakthrough Device Designation by the FDA for diagnosing myocardial ischemia and infarction. Additionally, Genetesis received a second FDA Breakthrough Device Designation in 2023 for the non-invasive diagnosis of myocardial ischemia. CardioFlux has been recognized for its ability to diagnose coronary microvascular dysfunction and detect functionally significant ischemia at its earliest stages. The device has also been tested with patients who struggle with claustrophobia, with most finding the experience manageable without medication. Genetesis has raised $40 million in overall funding and has been recognized with several awards, including the 2022 Forbes 30 Under 30 in Healthcare and the Nvidia Inception Award for Best AI Social Impact Startup. The company partners with various institutions to evolve the standard of care and has a research roadmap that spans from scientific exploration to clinical application. The MAGNETO trial, which enrolled 390 patients from the emergency department with suspected acute coronary syndrome, demonstrated that MCG could eliminate the need for downstream testing and significantly reduce the length of stay for patients presenting with chest pain. Genetesis has a 4.5/5 star rating on Glassdoor, reflecting its positive workplace environment.